1-Methyl-4-{[5-(1,2,3-thiadiazol-4-yl)thiophen-2-yl]sulfonyl}piperazine

Catalog No.: 
ACBUXU103
CAS No.: 
320421-84-9
Molecular Formula: 
C11H14N4O2S3
Molecular Weight: 
330.46
1-Methyl-4-{[5-(1,2,3-thiadiazol-4-yl)thiophen-2-yl]sulfonyl}piperazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
10mg90%$377.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Methyl-4-{[5-(1,2,3-thiadiazol-4-yl)thiophen-2-yl]sulfonyl}piperazine
IUPAC Name4-(5-((4-methylpiperazin-1-yl)sulfonyl)thiophen-2-yl)-1,2,3-thiadiazole
Molecular FormulaC11H14N4O2S3
Molecular Weight330.46
SMILESO=S(N1CCN(C)CC1)(C2=CC=C(C3=CSN=N3)S2)=O
InChI KeyAJOCKLBNRVGFTA-UHFFFAOYSA-N
Synonym1-METHYL-4-([5-(1,2,3-THIADIAZOL-4-YL)-2-THIENYL]SULFONYL)PIPERAZINE;1-methyl-4-{[5-(1,2,3-thiadiazol-4-yl)thiophen-2-yl]sulfonyl}piperazine;Piperazine, 1-methyl-4-[[5-(1,2,3-thiadiazol-4-yl)-2-thienyl]sulfonyl]-
CAS No.320421-84-9

Synthetic Route by SureRoute

1. ACBUXU103 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACJACD865 route compound structure diagram
    ACJACD86534352-59-5In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBUXU103 route product structure diagram
    ACBUXU103320421-84-9
Inquiry

2. ACBUXU103 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBUXU103 route product structure diagram
    ACBUXU103320421-84-9
Inquiry

3. ACBUXU103 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACBUXU103 route product structure diagram
    ACBUXU103320421-84-9
Inquiry

Comments (0)